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How Leiomodin and Tropomodulin use a common
fold for different actin assembly functions
Malgorzata Boczkowska1,*, Grzegorz Rebowski1,*, Elena Kremneva2,*, Pekka Lappalainen2 & Roberto Dominguez1
How proteins sharing a common fold have evolved different functions is a fundamental
question in biology. Tropomodulins (Tmods) are prototypical actin ﬁlament pointed-end-
capping proteins, whereas their homologues, Leiomodins (Lmods), are powerful ﬁlament
nucleators. We show that Tmods and Lmods do not compete biochemically, and display
similar but distinct localization in sarcomeres. Changes along the polypeptide chains of
Tmods and Lmods exquisitely adapt their functions for capping versus nucleation. Tmods have
alternating tropomyosin (TM)- and actin-binding sites (TMBS1, ABS1, TMBS2 and ABS2).
Lmods additionally contain a C-terminal extension featuring an actin-binding WH2 domain.
Unexpectedly, the different activities of Tmods and Lmods do not arise from the Lmod-
speciﬁc extension. Instead, nucleation by Lmods depends on two major adaptations—the loss
of pointed-end-capping elements present in Tmods and the specialization of the highly
conserved ABS2 for recruitment of two or more actin subunits. The WH2 domain plays only
an auxiliary role in nucleation.
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T
ropomodulins (Tmods) constitute a conserved family of
four isoforms that work in conjunction with one of several
tropomyosin (TM) isoforms to cap the pointed end of
actin ﬁlaments in cytoskeletal structures characterized by their
uniform distribution of the lengths of actin ﬁlaments1. These
structures include the sarcomere of cardiac and skeletal muscle
cells and the spectrin-based membrane skeleton1,2. The unique
domain organization of Tmods is precisely matched to their core
function in pointed end capping, and consists of alternating TM-
and actin-binding sites (TMBS1, ABS1, TMBS2 and ABS2).
While TMBS1, ABS1 and TMBS2 feature helical segments, they
lie within the otherwise unstructured N-terminal B160-amino-
acid (aa) region of Tmod3–5. In contrast, most of ABS2,
comprising the C-terminal B200-aa region of Tmods, is folded
as a leucine-rich repeat (LRR) domain6. We recently showed that
ABS1 binds on top of the ﬁrst actin subunit at the pointed end of
the actin ﬁlament, adopting an extended but ordered structure,
whereas ABS2 binds at the interface between the ﬁrst three
subunits of the ﬁlament, interacting mostly with the second
subunit7.
Leiomodins (Lmods) are related to Tmods, and constitute a
subfamily of three isoforms: Lmod1, expressed preferentially in
differentiated smooth muscle cells; and Lmod2 and Lmod3,
expressed more abundantly in skeletal and cardiac muscles8–12.
Lmods are distinguished from Tmods by the presence of a
C-terminal extension, featuring a proline-rich region and a WH2
domain. The WH2 domain is a widespread actin monomer-
binding motif13,14, frequently found C-terminally to proline-rich
regions among cytoskeletal proteins that nucleate actin
polymerization15. The unique characteristics of the C-terminal
extension suggested that Lmods could function as actin ﬁlament
nucleators, which we initially demonstrated for Lmod2 (ref. 11),
and was recently also shown for Lmod3 (ref. 10). Emphasizing
the physiological importance of Lmods, recent studies have
established that Lmod3 deﬁciency results in nemaline myopathy
in mice16, and human patients affected by an unusually lethal
form of this disease carry mutations in the gene encoding Lmod3
(ref. 10).
The main feature deﬁning an actin ﬁlament nucleator is
the presence of multiple actin-binding sites, allowing these
molecules to recruit two or more actin subunits to form a
polymerization nucleus (or seed). Therefore, we had initially
proposed that the C-terminal extension, absent in Tmods,
was the main factor responsible for the nucleation activity of
Lmods, since it could mediate the recruitment of an additional
actin subunit through the WH2 domain11. However, our recent
ﬁnding that the ABS2 of Tmods contacts three actin subunits in
the ﬁlament7 raised two important questions: (a) why are Tmods
unable to nucleate polymerization if they can interact with up to
three actin subunits at the pointed end of the ﬁlament? and (b)
does ABS2 play a more prominent role in Lmod-based nucleation
than previously anticipated? By addressing these questions
here, we made several important ﬁndings. We show that
ABS2, and not the C-terminal extension, is the main factor
distinguishing Lmods and Tmods as ﬁlament nucleators and
pointed-end-capping proteins, respectively. This was a surprising
ﬁnding since ABS2 is also the most highly conserved region
among these proteins. We further show that, through a series of
local changes along the polypeptide chain, Lmods have lost
speciﬁc features that allow Tmods to cap the pointed end, while
acquiring new features required for nucleation. Consistently, we
established that Tmods and Lmods do not compete biochemically
with each other, and display similar but distinct localization in
muscle sarcomeres. Finally, we found that the WH2 domain-
containing extension of Lmods plays only an auxiliary role in
nucleation.
Results
Smooth muscle Lmod1 is a ﬁlament nucleator. Lmod isoforms
differ considerably, and Lmod1 is the most divergent of the three
isoforms (Fig. 1a and Supplementary Fig. 1a). The region
N-terminal to ABS2 of Lmod1 comprises B300 aa, which is
much longer than in Tmods or other Lmods, whereas its
C-terminal extension is shorter than in other Lmods. While the
striated muscle isoforms Lmod2 (ref. 11) and Lmod3 (ref. 10)
have been shown to nucleate actin polymerization in vitro,
smooth muscle Lmod1 remains uncharacterized, and problems
with protein degradation have hampered its study. Here we
obtained pure proteins by using N- and C-terminal afﬁnity tags
followed by gel ﬁltration (Methods and Supplementary Fig. 2),
and proteins were used in experiments within 3 days after pur-
iﬁcation. Using the pyrene actin polymerization assay, we found
that Lmod1 had strong nucleation activity, comparable to that of
Arp2/3 complex and Lmod2, and this activity increased with
Lmod1 concentration (Fig. 1b). We thus conclude that despite
extensive differences between Lmod isoforms, they all share a
common ability to strongly activate actin polymerization in vitro,
and thus the elements necessary for this activity must be
conserved among isoforms.
Lmod and Tmod domains in ﬁlament nucleation versus capping.
Tmod1 has strong pointed-end-capping activity7,17 but, as
conﬁrmed here (Fig. 1b), it completely lacks nucleation activity
over a range of concentrations. For this reason, we had previously
proposed that the C-terminal extension of Lmods, which is
missing in Tmods, was the main factor responsible for their
nucleation activity11. To more directly test this hypothesis, we
asked whether adding the C-terminal extension of human Lmod2
C terminally to human Tmod1 would be sufﬁcient to produce a
ﬁlament nucleator. Note also that the sequence of human Lmod2
was corrected in databases since the submission of our original
work11, and the corrected sequence used here includes changes
both N and C terminal to ABS2 (see Methods and Supplementary
Fig. 1). To our surprise, however, the hybrid construct Tmod1–
Lmod2C (Fig. 1a), displayed limited nucleation activity, which
increased only slightly with concentration, and was signiﬁcantly
lower than that of either Lmod1 or Lmod2 (Fig. 1b). Conversely,
removing the C-terminal extension of Lmod2 lowered its
nucleation activity, but the resulting construct (Lmod2N-ABS2)
was a more powerful nucleator over a rage of concentrations than
Tmod1 with addition of the C-terminal extension (Fig. 1c).
These results suggest that regions other than the C-terminal
extension are the main source of the functional differences
between Lmods and Tmods. To more precisely map the source of
these differences, we deleted the region N-terminal to ABS2 of
Lmod2 (construct Lmod2ABS2-C), which resulted in a relatively
minor drop in activity (Fig. 1c). What is more, the isolated ABS2
of Lmod2 still retained substantial nucleation activity, which
increased with concentration (Fig. 1c). Similar results were
obtained with Lmod1, although in this case removing the
N-terminal region had nearly no effect on the nucleation activity,
and the isolated ABS2 had even stronger activity than that of
Lmod2 (Fig. 1d).
Other than the WH2 domain, the C-terminal extension of
Lmods contains a proline-rich region, which is a potential
proﬁlin–actin-binding site. Thus, we tested the effect of proﬁlin
on Lmod1-mediated nucleation (Supplementary Fig. 3). Proﬁlin
is known to inhibit spontaneous actin nucleation and pointed-
end elongation18. Similarly, proﬁlin inhibited in a concentration-
dependent manner the nucleation activity of both Lmod1FL and
Lmod1ABS2, lacking the proline-rich region. We thus conclude
that, as previously observed with Lmod2 (ref. 11), the proline-rich
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region of Lmod1 is not implicated in the recruitment of
proﬁlin–actin for nucleation.
Together, these results suggest that the C-terminal extension
plays a secondary role in Lmod-mediated nucleation, whereas
ABS2 emerges as the main source of the differences between
Lmods and Tmods. This was a surprising ﬁnding, because ABS2
is also the most highly conserved region among these proteins
(Supplementary Fig. 1).
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Figure 1 | Domains of Lmod and Tmod and actin nucleation. (a) Domain organization of Tmod1 and Lmods, and design of the Tmod1–Lmod2c hybrid
construct. Numbers under the diagrams indicate the boundaries of domains. For Tmod1, the helix of ABS1 (aa 67–81) and the LRR portion of ABS2
(aa 181–337) are highlighted. (b) Nucleation activity of full-length Lmod1, Lmod2 and the hybrid construct Tmod1–Lmod2C as compared with Tmod1 and the
Arp2/3 complex (25 nM, activated by 100nMN-WASP WCA). The left two graphs show time courses of polymerization of 2mM Mg–ATP–actin
(6% pyrene labelled) in the presence of 25 nM of the indicated proteins (colour coded) or the buffer control (black). The graph on the right shows the
concentration dependence of the polymerization rates, displayed as the mean of three experiments±s.e.m. (c,d) Contribution of the various domains of
Lmod1 (c) and Lmod2 (d) to the nucleation activity. The graphs on the left and the right show, respectively, the time course of polymerization of 2 mM
Mg–ATP–actin in the presence of 25 nM Lmod fragments (colour coded) or buffer (black) and the concentration dependence of polymerization rates.
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Role of the N-terminal region in nucleation versus capping.
Tmods bind TM through two different sites5, and this interaction
enhances their pointed-end-capping efﬁciency4,7,17. Comparison
of 50 Tmod and 50 Lmod sequences separately and together
shows that only the ﬁrst of these sites in conserved in Lmods
(Fig. 2a and Supplementary Figs 1 and 4). While we showed
above that in the absence of TM N-terminal deletions had a
relatively minor effect on the nucleation activity of Lmods,
we previously found that TM increases the activity of Lmod2FL
(refs 11,19). A similar effect was observed here over a range of
concentrations with Lmod1FL (Fig. 2b).
It was previously thought that ABS1 in Tmods consisted
mostly of an a-helix1, which appeared to be conserved in
Lmods11. However, we recently found that ABS1 is longer than
anticipated, comprising in addition to the a-helix an extended
region that binds along subdomains 2 and 1 of the ﬁrst actin
subunit of the ﬁlament7. Sequence analysis reveals that only the
N-terminal portion of ABS1 is somewhat conserved in Lmods
(Fig. 2a and Supplementary Figs 1 and 4), which together with the
minor effect of N-terminal deletions described above (Fig. 1c,d)
made us question whether this interaction was conserved in
Lmods. Consistent with our previous ﬁndings7, Tmod1ABS1
(Fig. 2a) bound one actin monomer (stabilized with LatB) with
micromolar afﬁnity by isothermal titration calorimetry (ITC)
(Fig. 2c). In contrast, the equivalent constructs of Lmod1 and
Lmod2 did not bind LatB-actin. We thus conclude that the
interaction of ABS1 with actin, which is critical for pointed-end
ﬁlament capping by Tmods4,7, is not conserved in Lmods and
may not be required for nucleation.
Fine-tuning ABS2 for nucleation versus capping. While ABS2 is
generally well conserved among Tmods and Lmods, we noticed
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Figure 2 | The different activities of Tmod and Lmod result from differences in their interactions with actin and TM. (a) Sequence conservation analysis
of Tmod and Lmod (see also Supplementary Fig. 1). Fifty Tmod (purple) and ﬁfty Lmod (orange) sequences were aligned separately or together (blue),
and residue conservation scores were calculated with the program Scorecons29 and plotted on the human Tmod1 sequence (the scores of residues absent
in Tmod1 are not shown). The Tmod1 diagram on top indicates the boundaries of the TM- and actin-binding sites. Diagrams on the bottom illustrate
ABS1 constructs, and hybrid Tmod1 (magenta)/Lmod (green) ABS2 constructs (TL1ABS2, TL2ABS2 and Tmod1ABS2Mut). The 11 residues of Tmod1ABS2
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that sequence conservation drops sharply at the N- and
C-terminal ends of the domain (Fig. 2a and Supplementary Figs 1
and 4). The differences at the C-terminal end appeared less
critical for function, because Tmod1 residues that interact with
actin (up to Arg-343) (ref. 7) tend to be conserved in Lmods.
However, the variable region at the N terminus, comprisingB22
aa (Tmod1 residues 164–186), is critical for Tmod-mediated
capping, since it covers the pointed end of the second subunit
of the ﬁlament through interactions with actin subdomain 2
(Supplementary Fig. 4). Mutations in this region markedly reduce
pointed-end capping7. Therefore, together with ABS1 and
TMBS2, Lmods also appear to have lost this important capping
element of ABS2.
While the divergent regions of ABS2 interact exclusively with
the second actin subunit of the ﬁlament, the more highly
conserved middle portion of the domain interacts at the interface
between the ﬁrst three subunits of the ﬁlament7. Therefore, one
way in which Lmods could have acquired nucleation activity is by
reinforcing these interactions. To test this hypothesis we designed
Tmod–Lmod ABS2 hybrid constructs aimed at combining their
respective pointed-end-capping and nucleating activities (Fig. 2a).
The ﬁrst two constructs (TL1ABS2 and TL2ABS2) consisted of
Tmod1 residues 164–229 and Lmod1 residues 365–486 (or
Lmod2 residues 246–367). Strikingly, at 25 nM both TL1ABS2 and
TL2ABS2 had nucleation activities comparable to that of their
full-length Lmod counterparts, albeit at higher concentrations
the full-length proteins displayed higher activities (Fig. 3a).
Importantly, both TL1ABS2 and TL2ABS2 had much higher activity
than the wild-type ABS2 domains from which they originate
(Fig. 3a). In the third construct (Tmod1ABS2Mut, Fig. 2a),
11 residues of Tmod1ABS2 predicted to fall at the interface
between three actin subunits in the ﬁlament were replaced by the
corresponding residues in Lmod1, whose ABS2 has stronger
nucleation activity than that of Lmod2. The 11 positions mutated
were selected such that they were conserved within the separate
Lmod and Tmod subfamilies, but not across subfamilies (Fig. 2a
and Supplementary Fig. 1). Remarkably, contrary to Tmod1ABS2,
Tmod1ABS2Mut had strong nucleation activity that fell in between
those of TL1ABS2 and TL2ABS2, and was much higher than that of
Lmod1ABS2 (Fig. 3a).
We previously found that Tmod1ABS2 binds a single actin
monomer stabilized with gelsolin segment 1 (GS1) with
micromolar afﬁnity7. However, because ﬁlament nucleators are
distinguished by their ability to recruit two or more actin subunits
to form a nucleus, we asked whether the ABS2 variants displaying
nucleation activity would bind two or more subunits. To test this
idea, we used ITC. To prevent actin polymerization in these
experiments, we used either LatB or GS1, both of which form 1:1
complexes with actin that cannot add along the long pitch helix of
the actin ﬁlament (that is, binding of more than two actin
subunits under these conditions is unlikely). Each experiment was
ﬁtted to either a one-site (N¼ 1) or a two-independent-site
(N¼ 2) binding model, and the best model was chosen based on
the w2 value. As before7, the titration of Tmod1ABS2 into actin
(GS1) ﬁtted equally well to both models, and thus the simplest
solution (N¼ 1) was sufﬁcient to explain this interaction
(Supplementary Fig. 5a). The afﬁnity of the interaction was
relatively low, KD¼ 56±5 mM (when N is included in ﬁtting).
This experiment could not be performed with LatB-actin, because
the complex precipitated in the ITC cell. In contrast to
Tmod1ABS2, all the ABS2 constructs with nucleation activity
bound two actin subunits with either LatB or GS1 (Fig. 3b and
Supplementary Figs 5 and 6). (Lmod1ABS2 precipitated during the
experiment and could not be analysed.) Invariably, the ﬁrst
binding site had nanomolar afﬁnity, whereas the afﬁnity of the
second site was in the micromolar range. Note, however, that the
afﬁnities obtained with GS1-actin were always somewhat lower
than those measured with LatB-actin, suggesting that GS1
allosterically lowers the afﬁnity of ABS2 for actin. More
generally, any factor preventing actin polymerization, including
low salt, could in principle affect binding to monomeric actin.
Therefore, rather than the exact afﬁnity values, what these
experiments tell us is that capping versus nucleation by ABS2
depends on whether this domain binds one (Tmod) or more
(Lmod) actin subunits.
Structural bases of ﬁlament nucleation by ABS2. The obser-
vations described above raised several questions that required
high-resolution structural information to be addressed, including:
(a) how do the functional differences between the ABS2 of Tmods
and Lmods correlate with structural differences? (b) are the
hybrid Tmod-Lmod constructs properly folded? and (c) how does
the ABS2 of a nucleator interact with actin compared with that of
Tmod1 (ref. 7)? Three high-resolution crystal structures help us
address these questions.
The structure of Lmod1ABS2, the strongest nucleator among the
naturally occurring ABS2s analysed here (Figs 1d and 3a), was
determined at 1.54Å resolution (Table 1 and Supplementary
Fig. 7a), and shows residues Ala-314 to Gln-486. The structure
superimposes well with that of Tmod1ABS2 (refs 6,7), with a root
mean squared deviation (r.m.s.d.) of 0.57Å for 131 equivalent Ca
atoms (Fig. 4a and Supplementary Movie 1). The major
differences occur at the N and C termini of the domain,
consistent with the lower sequence conservation observed within
these areas (Fig. 2a and Supplementary Fig. 1). The C-terminal
helix is rotated B4 compared with Tmod1ABS2 (Fig. 4a).
However, this difference does not necessarily correlate to
function, since the C-terminal helix is generally ﬂexible and
changes conformation when bound to actin7. The differences at
the N terminus appear to be more important. Indeed, the loop of
Tmod1 implicated in pointed-end capping (Tyr-170 to Val-183)
is missing in Lmods, and the corresponding region of Lmod1
visualized in the electron density map (Ala-314 to Phe-318) is
oriented in the opposite direction to that of Tmod1ABS2 in the
unbound6 as well as the actin-bound7 structures.
The structure of TL1ABS2, the strongest of the hybrid nucleators
(Fig. 3a), was determined at 2.1 Å resolution (Table 1 and
Supplementary Fig. 7b), and shows Tmod1 residues Glu-177 to
Phe-229 followed by Lmod1 residues Ala-365 to Gln-486 (Fig. 4b
and Supplementary Movie 2). The structure superimposes well
with those of Tmod1ABS2 (r.m.s.d. of 0.41Å for 125 equivalent Ca
atoms) and Lmod1ABS2 (r.m.s.d. of 0.27Å for 124 equivalent Ca
atoms). What is more, the side chains in the hydrophobic core of
TL1ABS2 have the same rotamer orientations as in the two parent
structures. Therefore, the strong nucleation activity of TL1ABS2 is
solely due to its amino-acid composition, and not to changes in
the overall structure.
The structure of TL1ABS2 bound to actin was determined by
fusing this domain C terminally to GS1, using a 9-aa ﬂexible
linker in between the two proteins (GGSGGSGGS), as done
previously for Tmod1ABS2 (ref. 7). Since TL1ABS2 binds at least
two actins (Fig. 3b), crystallization trials were conducted with the
1:1 puriﬁed complex (see Methods), as well as with addition of
excess GS1-actin or LatB-actin. However, crystals were only
obtained for the 1:1 complex. The structure was determined at
2.4 Å resolution (Table 1 and Supplementary Fig. 7c). Overall, the
structure is very similar to that of Tmod1ABS2-actin. However,
when the actin portion of these two structures are superimposed,
TL1ABS2 appears shifted on the actin surface byB2.5 Å compared
with Tmod1ABS2 (Fig. 4c and Supplementary Movie 3).
As a consequence, when the structure of TL1ABS2-actin is
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superimposed onto the second actin subunit of the
3.7 Å-resolution EM structure of the ﬁlament20, as proposed for
Tmod1ABS2 (ref. 7), this shift inserts TL1ABS2 deeper into the
groove formed at the interface between the three actin subunits
(Fig. 4d and Supplementary Movie 4). The residues of ABS2 that
interact in this groove form part of the so-called ‘ascending loops’
of the LRR domain, which connect the b-strand and a-helix of
each repeat, and are commonly implicated in protein–protein
interactions21. Strikingly these loops comprise several residues
that are independently conserved among Tmods and Lmods, but
not across the two subfamilies (Fig. 2a and Supplementary Figs 1
and 4). As shown above, replacing 11 such residues in Tmod1ABS2
by their Lmod1 counterparts was sufﬁcient to produce the
powerful nucleator Tmod1ABS2Mut (Figs 3a and 4e).
Role of Lmod and Tmod domains in cellular localization. The
results described above suggest that Lmods have lost key elements
needed for pointed-end capping and localization in Tmods,
including ABS1, TMBS2 and the N terminus of ABS2. On the
other hand, we found that the nucleation activity of Lmods
depends strongly on ABS2 (Fig. 3), but is additionally modulated
by interaction of the N-terminal region with TM (Fig. 2b), which
binds along the length of the actin ﬁlament. These observations
prompted us to explore the role of the N-terminal region and
ABS2 in localization of Lmod versus Tmod. For this, Lmod and
Tmod constructs were expressed in neonatal rat cardiomyocytes.
Co-expression of Tmod1FL-green ﬂuorescent protein (GFP)
with either Tmod1ABS2-mCherry or Tmod1N-mCherry conﬁrmed
that both the N- and C-terminal capping domains4,22 are
required for proper pointed-end localization of Tmod1
(Fig. 5a–d). As expected, Tmod1FL localized to ﬁlament pointed
ends near the M-line marker myomesin (Supplementary Fig. 8a),
and well segregated from the Z-line marker a-actinin (Fig. 5c).
Both Tmod1FL and a-actinin showed well-deﬁned periodicity in
their average fast Fourier transform power spectra, with a power
peak frequency of 0.572 mm 1, corresponding to a distance
of 1.75 mm between M lines or Z lines, respectively (Fig. 5d).
In contrast, Tmod1ABS2 and Tmod1N showed more diffuse
localization along myoﬁbrils, characterized by the loss of
periodicity in their power spectra. This is consistent with the
notion that the N-terminal region and ABS2 are both required
for pointed-end capping by Tmod4, which is speciﬁcally
accomplished by interactions of ABS1 and the N-terminal
portion of ABS2 with the pointed ends of the ﬁrst and second
subunits of the ﬁlament, respectively7.
In light of these results, our analysis of Lmod2 revealed a few
surprises. As we previously reported11,19, Lmod2FL was enriched
near M lines (Fig. 5e,h and Supplementary Fig. 8b), somewhat
similar to Tmod1FL. However, contrary to Tmod1FL, Lmod2FL
also showed diffuse localization along the length of the
actin ﬁlaments in sarcomeres, with the exclusion of Z lines.
Furthermore, while in the average power spectrum Lmod2FL
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displayed clear periodicity (Fig. 5h), line scans showed that its
distribution was broader than that of Tmod1FL (compare
Fig. 5c,g). Lmod2ABS2 displayed relatively uniform localization
along the length of the actin ﬁlaments, except Z lines, but unlike
Lmod2FL was not enriched near M lines (Fig. 5e,g). More
surprising, however, was the ﬁnding that Lmod2N, which lacks
ABS1 and TMBS2 (Fig. 2a,c), was enriched near M lines
(Fig. 5f,g). Unlike Tmod1ABS2 and Tmod1N, the power spectra
of both Lmod2ABS2 and Lmod2N displayed clear periodicity, with
power peaks at 0.59 and 0.55 mm 1, respectively (Fig. 5h). It thus
appears that the N-terminal region is important for Lmod2FL
enrichment near M lines, whereas ABS2 drives its localization
along the length of the actin ﬁlaments. Because Lmod2N lacks
ABS1 and TMBS2, its localization near pointed ends must depend
on other interactions, possibly involving TMBS1 and the
negatively charged sequence replacing TMBS2 (Supplementary
Fig. 1). On the other hand, the lack of a pointed-end-binding
sequence at the N terminus of ABS2 (Fig. 2a) allows it to bind in
every groove between three actin subunits along the entire length
of the ﬁlament (Fig. 4d). Tmod’s ABS2 cannot do this, because it
interacts mostly with a single actin subunit (Supplementary
Fig. 5a) and has a pointed end directing sequence at the N
terminus7.
Lmod1 differs substantially from Lmod2 (Fig. 1a and
Supplementary Fig. 1a) and is predominantly expressed in
smooth muscle cells8,9,12. Therefore, while here we exogenously
expressed Lmod1 in cardiomyocytes, these results must be viewed
as preliminary. Both Lmod1FL and Lmod1N unexpectedly
localized near Z lines, forming a double band on both sides
from a-actinin, and were also slightly enriched near M lines
(Supplementary Fig. 9). Lmod1ABS2 localized uniformly along
myoﬁbrils, without apparent periodicity. Our interpretation of
these results is that cardiomyocytes lack smooth muscle-speciﬁc
interactions necessary for Lmod1FL and Lmod1N enrichment near
pointed ends, whereas the closely related ABS2s of Lmod1 and
Lmod2 share the ability to bind along the length of the actin
ﬁlament.
Tmod does not compete with Lmod during nucleation. We
have shown here that Tmod and Lmod display similar but
distinct localization in muscle sarcomeres. We have also shown
that Lmod strongly nucleates actin polymerization, whereas
Tmod does not. Finally, we have demonstrated that Lmod has
lost key features required for pointed-end capping by Tmod,
including ABS1, TMBS2 and the N terminus of ABS2. The
question remains, does these two related families of proteins
compete with each other for binding to the pointed end? In other
words, does Lmod remain bound after nucleation to cap the
pointed end the way Arp2/3 complex does? Pointed-end
elongation/depolymerization is slow, such that any effect of Lmod
on pointed-end kinetics is masked by its strong nucleation
Table 1 | Crystallographic data and reﬁnement statistics.
Lmod1ABS2 TL1ABS2 GS1-TL1ABS2:actin
Data collection
Space group P 21 21 21 P 21 21 21 P 1 21 1
Cell dimensions
a, b, c (Å) 49.02, 52.19, 75.89 53.47, 53.94, 75.60 71.23, 70.80, 81.32
a, b, g () 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 101.74, 90.0
Wavelength (Å) 1.5418 1.5418 1.5418
Resolution (Å) 41.2–1.54 (1.64–1.54)* 43.9–2.1 (2.2–2.1) 39.8–2.4 (2.49–2.4)
Rmerge (%) 3.7 (43.6) 5.8 (30.2) 8.4 (30.8)
I/s I 23.9 (2.4) 18.9 (2.0) 15.2 (2.1)
No. of unique reﬂections 29,387 (4,851) 12,763 (1,264) 27,918 (1,649)
Completeness (%) 98.6 (92.2) 95.5 (73.1) 89.5 (51.1)
Redundancy 5.2 (2.3) 7.0 (1.2) 5.2 (1.8)
Wilson B-factor (Å2) 13.13 26.0 26.8
Reﬁnement
Resolution (Å) 41.2–1.54 (1.59–1.54) 43.9–2.1 (2.17–2.10) 39.8–2.4 (2.49–2.4)
No. of reﬂections 29,335 (2,528) 12,725 (896) 27,905 (1,556)
Completeness (%) 98.6 (86.3) 95.5 (69.2) 89.5 (50.5)
Rwork (%) 15.6 (26.3) 19.1 (23.6) 18.5 (24.6)
Rfree (%) 17.7 (31.1) 25.4 (33.0) 24.3 (29.8)
No. of residues 173 184 682
No. of atoms 1,692 1,547 5,582
Protein 1,461 1,425 5,366
Ligand 40 9 34
Solvent 191 113 182
r.m.s. deviations
Bond lengths (Å) 0.010 0.015 0.015
Bond angles () 1.29 1.66 1.70
B-factors (Å2)
Protein 16.4 39.2 38.0
Ligand 36.7 59.0 21.5
Solvent 30.3 41.0 31.9
Ramachandran(%)
Favoured 98.0 99.0 97.0
Outliers 0.0 0.0 0.15
PDB Code 4Z79 4Z8G 4Z94
*Values in parenthesis correspond to highest resolution shell.
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activity in bulk or total internal reﬂection ﬂuorescence (TIRF)
assays. Therefore, to address this question we tested whether
nucleation by Lmod was in any way affected by the presence of
Tmod. Yet, we found that even a fourfold excess of Tmod1 had
no effect on the nucleation activity of Lmod2 alone or in the
presence of TM (Fig. 6a,b). These results allow us to conclude that
Tmod1 and Lmod2, which are both expressed in sarcomeres1,11,
do not compete biochemically with each other. Tmod binds with
very high afﬁnity to the pointed end, particularly in the presence
of TM7,17, and it would be expected to cap the pointed end of the
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Figure 5 | Localization of Tmod1 and Lmod2 constructs in sarcomeres. (a,b) Cardiomyocytes co-transfected on day 1 with Tmod1FL-GFP and
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Lmod2 constructs are deﬁned in Methods and in Fig. 1a. Scale bars, 10mm.
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Lmod-nucleated ﬁlaments. Therefore, if Lmod remained bound
to the pointed end after nucleation it should be released by Tmod,
thus increasing the amount of Lmod available for nucleation. The
fact that bulk polymerization does not increase with the addition
of Tmod strongly suggests that Lmod does not stay bound at the
pointed end after nucleation.
Discussion
By studying Tmod and Lmod in parallel, we have established here
how these two related subfamilies of proteins have evolved
different functions—pointed-end capping and ﬁlament nuclea-
tion, respectively. We showed that Tmod and Lmod do not
compete biochemically with each other, and display similar but
distinct localization in muscle sarcomeres (Figs 5 and 6). Rather
unexpectedly, we found that the C-terminal extension of Lmods,
which distinguishes them from Tmods, was not the main source
of the functional differences between the two subfamilies. Thus,
Tmod failed to gain strong nucleation activity even after addition
of the C-terminal extension of Lmod, whereas Lmod retained
signiﬁcant nucleation activity after removal of this extension. This
was true for both Lmod2 and the smooth muscle isoform Lmod1,
characterized here for the ﬁrst time. It thus appears that in Lmod
the WH2 domain plays only an auxiliary role in nucleation,
possibly by helping to recruit the third actin subunit of the
polymerization seed, which also interacts with ABS2 and the ﬁrst
two actin subunits (Fig. 4d).
The emergence of ABS2 as the main source of the differences
between Tmod and Lmod was unexpected, since this domain
corresponds to the most highly conserved region between these
two subfamilies. The transition from capping to nucleation within
this domain involves two major adaptations. First, in Lmod ABS2
lacks the N-terminal region that in Tmod interacts with the
DNase I-binding loop at the pointed end of the second actin
subunit of the ﬁlament7. In this way, Lmod has lost a major
determinant of pointed-end capping, which would put it in
competition with Tmod in vitro and in cells. Second, the
ascending loops of the LRR domain have different sequence in
Lmod compared with Tmod. These loops bind in the groove
formed at the interface between three actin subunits of the
ﬁlament. We have shown here that it is sufﬁcient to mutate 11
amino acids within these loops to turn Tmod’s ABS2 into a
powerful nucleator. This is achieved by increasing the afﬁnity of
this domain for two or more actin subunits, which would
interfere with Tmod’s capping activity in cells. Curiously, the
hybrid constructs combining the capping N terminus of Tmod1’s
ABS2 with the added afﬁnity of Lmod’s ABS2 were better
nucleators than those of the wild-type proteins. This surprising
result can now be rationalized. The ABS2 of Lmod has the
required afﬁnity to recruit two or more subunits for nucleation,
but by adding a pointed-end-binding element, we have limited
the ability of this domain to bind along the length of the ﬁlament
when in isolation (Fig. 5), that is, the hybrid constructs emphasize
nucleation at the expense of ﬁlament side-binding. These
constructs constitute the smallest single-domain protein with
strong nucleation activity identiﬁed thus far.
Several adaptations of Lmod for nucleation occur within the
N-terminal region, including the lack of ABS1 and TMBS2
necessary for pointed end capping by Tmod. Despite these
changes, however, the N-terminal region of Lmod2 localizes near
M-lines on its own, whereas that of Tmod does not (Fig. 5). TM
binding through TMBS1 is probably not sufﬁcient to explain this
difference, since this site is conserved in both Lmod1 and Tmod1.
The sequence between TMBS1 and ABS2 is very different in
Tmod1, Lmod1 and Lmod2, and probably holds the key to
understand their different localizations, which will be the subject
of future investigation. Finally, Lmod’s N-terminal region
participates in nucleation through interaction with TM, which
upregulates this activity, a fact that we had previously observed
with Lmod2 (refs 11,19) and is conﬁrmed here for Lmod1.
In summary, nucleation in Lmod is the result of two major
adaptations—the loss of capping elements present in Tmod and
the specialization of ABS2 for recruitment of two or more actin
subunits. The N-terminal region is necessary for localization, and
modulates the nucleation activity through interaction with TM,
whereas the WH2 domain-containing C-terminal extension adds
to the overall nucleation activity, likely by securing the binding of
the third actin subunits of the nucleus.
Methods
Proteins. The exact amino-acid composition of all the proteins, fragments and
hybrid constructs used in this study are schematically depicted in the main ﬁgures
of the paper (Figs 1 and 2a), whereas all the primers used in cloning are listed in
Supplementary Table 1.
Since our original characterization of human cardiac Lmod2 (ref. 11), the
sequence has been corrected (UniProt: Q6P5Q4-1). The originally deposited
sequence contained two large deletions of 32 aa (residues 99–130) and 20 aa
(residues 428–447) within the N- and C-terminal regions, respectively. To build the
correct sequence, the missing amino acids were added by PCR to an incomplete
clone (IHS1382-8558565) previously purchased from Open Biosystems. The
primers coding for the missing amino acids also introduced silent EcoRI and XhoI
sites that were subsequently used for ligation of the ampliﬁed fragments. The
cDNA encoding for human Lmod1 (UniProt: P29536-1) was purchased from
Open Biosystems.
Most proteins expressed here were cloned between the NdeI and SapI sites of
vector pTYB1 (NEB). The ABS1 fragments were cloned between the SapI and XhoI
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sites of vector pTYB11 (NEB). These vectors comprise a chitin-binding domain for
afﬁnity puriﬁcation and an intein domain for self-cleavage of the afﬁnity tag after
puriﬁcation. Because full-length Lmods are highly susceptible to degradation, a
second afﬁnity puriﬁcation tag (a His-tag) was added at the N terminus during
cloning. The double afﬁnity puriﬁcation allows separating the full-length protein
from the degradation fragments. The cDNA encoding for human Tmod1 (UniProt:
P28289-1) and human gelsolin (UniProt: P06396-2) were purchased from
American Type Culture Collection. The Tmod1 fragments were cloned into vector
pTYB1 as described above. The 11 mutations of construct Tmod1ABS2Mut were
generated using the QuickChange mutagenesis kit (Stratagene). The hybrid
construct Tmod1–Lmod2C was obtained by introducing silent mutations at the
junction between the two proteins using the forward and reverse primers, such as
to produce a new MfeI restriction site that was then used for ligation. The hybrid
constructs TL1ABS2 and TL2ABS2 were obtained by amplifying fragments:
Tmod1164–229, Lmod1365–486 and Lmod2246–367 with primers introducing silent
NruI restriction sites at the junctions. The hybrid constructs GS1-TL1ABS2 was
obtained as described above, using as a template our previously published
GS1-Tmod1ABS2 (ref. 7) and ligating Lmod1365–486 after Tmod1 residue Phe-229.
All the ligation products were cloned between the NheI and SapI sites of vector
pTYB1. Human gelsolin segment 1 (GS1, residues 1–125, UniProt: P06396-2) was
cloned between the NdeI and EcoRI sites of vector pTYB12 (NEB). Human proﬁlin
1 (UniProt: P07737) was cloned between the SapI and EcoRI sites of vector
pTYB11 (NEB).
All the proteins were expressed in BL21(DE3) cells (Invitrogen), grown in
Terriﬁc Broth medium at 37 C until the OD600 reached a value of 1.5–2, followed
by 16 h at 20 C in the presence of 0.5mM isopropyl-b-D-thiogalactoside. Cells
were collected by centrifugation, re-suspended in 20mM HEPES pH 7.5, 500mM
NaCl, 1mM EDTA and 100 mM phenylmethyl sulfonyl ﬂuoride and lysed using a
microﬂuidizer (Microﬂuidics). All the proteins were ﬁrst puriﬁed on a chitin
afﬁnity column according to the manufacturer’s protocol (NEB). Full-length
Lmods were additionally puriﬁed on a Ni-NTA column (Qiagen). Finally, all the
proteins were puriﬁed by gel ﬁltration on a SD200HL 26/600 column (GE) in
20mM HEPES (pH 7.5) and 200mM NaCl.
Arp2/3 complex was puriﬁed from bovine brain as we have described23. Brieﬂy,
frozen brain was homogenized in Arp buffer (20mM HEPES (pH 7.5), 100mM
KCl, 1mM MgCl2, 1mM EGTA, 1mM dithiothreitol (DTT)) supplemented
with protease inhibitors and clariﬁed by centrifugation at 12,000g for 30min.
The supernatant was loaded onto a Macro-Prep High Q column (Bio-Rad)
pre-equilibrated with Arp buffer. The ﬂow-through, containing Arp2/3 complex,
was applied onto a WCA-afﬁnity column equilibrated with Arp buffer. Arp2/3
complex was eluted in 20mM Tris (pH 8.0), 25mM KCl, 400mM MgCl2, 1mM
EGTA and 1mM DTT, concentrated and further puriﬁed through an SD200HL 26/
600 column in Arp buffer. Actin24 and TM25 were puriﬁed as previously described.
Brieﬂy, actin was extracted from actomyosin acetone powder with G-buffer (2mM
Tris (pH 8.0), 0.2mM CaCl2, 0.2mM ATP, 0.5mM DTT and 0.01% NaN3),
centrifuged at 20,000g for 30min and polymerized with addition of 50mM NaCl
and 2mM MgCl2. The F-actin pellet was homogenized in G-buffer with the
addition of 10mM DTT. After 1 h, actin was dialysed exhaustively against G-buffer
to remove DTT and then centrifuged for 45min at 277,000g to pellet any F-actin
that did not depolymerize and any denatured actin. Tropomysin was extracted with
10mM Tris (pH 8.0), 0.5mM b-mercaptoethanol from the solid fraction remaining
after actin extraction from the acetone powder. The solution was clariﬁed by
centrifugation (16,000g for 1 h), puriﬁed by precipitation with 20% NH4SO4 and
centrifuged again. Tropomyosin was precipitated from the supernatant with 30%
NH4SO4, dialysed against 2mM Imidazole, 5mM b-mercaptoethanol and puriﬁed
on a hydroxyapatite column with a linear gradient of 1–200mM KH2PO4 (pH 7.0),
1 M KCl and 2mM DTT.
The concentration of all the proteins was determined spectrophotometrically,
using calculated extinction coefﬁcients (Supplementary Table 2).
Actin polymerization assay. Actin polymerization was measured as the ﬂuores-
cence increase resulting from the incorporation of pyrene-labelled actin into
ﬁlaments, using a Cary Eclipse ﬂuorescence spectrophotometer (Varian). Before
data acquisition, 200ml Mg–ATP–actin at 2 mM concentration (6% pyrene labelled)
was mixed with 5 ml of Lmod or Tmod constructs in 10mM Tris (pH 8.0), 1mM
MgCl2, 50mM KCl, 1mM EGTA, 0.2mM ATP, 0.5mM DTT and 0.1mM NaN3.
The ﬁnal concentration of Lmod or Tmod in the polymerization reaction ranged
between 5 and 500 nM (as indicated in the ﬁgures). In some experiments, 1 mM TM
was added to the actin before the addition of full-length Lmod1 or Lmod2, such
that the total volume remained constant at 200ml. Data acquisition started 10 s
after mixing. All the measurements were done at 25 C. Control experiments
were carried out with addition of 5 ml buffer. Relative polymerization rates were
calculated as the maximal slope of a polymerization curve (between 0.1 and 0.4 of
the maximum ﬂuorescence) divided by the maximal slope of the actin control.
Isothermal titration calorimetry. ITC measurements were carried out on a
VP-ITC apparatus (MicroCal). Samples were ﬁrst dialysed for 2 days against
20mM HEPES (pH 7.5), 100mM NaCl, 0.2mM ATP and 1mM DTT (ITC buffer).
In experiments with LatB-actin, LatB was added to the buffer at a LatB:actin ratio
of 1.2:1. In experiments with GS1-actin, actin and GS1 were mixed at a 1:1.5 molar
ratio, and the complex was puriﬁed by gel ﬁltration on a SD200HL 26/600 column
(GE Healthcare) in ITC buffer.
Each experiment was carried out over a range of temperatures from 10C to
30C, in 5C increments, and the optimal temperature for each reaction is shown
(Figs 2c and 3b and Supplementary Figs 5 and 6). Titrations consisted of 10-ml
injections, lasting for 10 or 20 s, with an interval of 4–5min between injections. The
concentration of the Lmod or Tmod titrant (listed in the ﬁgures) was 10- to 15-fold
higher than that of actin in the cell of total volume 1.44ml. The heat of binding was
corrected for the heat of injection, determined by injecting titrant into buffer (open
symbols in ﬁgures). Data were analysed using the program Origin (OriginLab
Corporation).
Crystallization, data collection and structure determination. Lmod1ABS2 at
10mgml 1 in 20mM HEPES (pH 7.5), 200mM NaCl and 1mM DTT was
crystallized at 20 C using the hanging drop method. The crystallization drop
consisted of a 1:1 (v/v) mixture of protein solution and well solution (100mM
HEPES (pH 7.5), 10% (v/v) isopropanol and 20% (v/v) polyethylene glycol 3,350).
For data collection, crystals were ﬂash frozen in liquid nitrogen from a
cryo-solution consisting of crystallization buffer with addition of 30% glycerol.
TL1ABS2 at 43mgml 1 in 20mM HEPES (pH 7.5), 300mM NaCl and 1mM DTT
was crystallized at 20 C using the sitting drop method. The crystallization drop
consisted of a 1:1 (v/v) mixture of protein solution and well solution (100mMMES
(pH 6.0), 200mM LiSO4 and 35% (v/v) 2-methyl-2,4-pentanediol (MPD)). For
data collection, crystals were ﬂash frozen in liquid nitrogen directly from a drop.
The 1:1 complex of GS1-TL1ABS2:actin was puriﬁed by gel ﬁltration on a
SD200HL 26/600 column and concentrated to 12.5mgml 1 in 20mM HEPES
(pH 7.5), 100mM NaCl, 0.2mM ATP, 0.2mM CaCl2 and 1mM DTT. Crystals
were obtained at 20 C using the hanging drop method. The crystallization drop
consisted of a 1:2 (v/v) mixture of protein solution and well solution (100mM Tris
(pH 8.8), 200mM LiSO4, 20% (v/v) polyethylene glycol 3,350 and 15% (v/v)
glycerol). For data collection, crystals were ﬂash frozen in liquid nitrogen from a
cryo-solution consisting of crystallization buffer with 30% (v/v) glycerol.
X-ray data sets were collected at 100 K using our home X-ray instrument:
Bruker X8 Prospector X-ray diffraction system, ﬁtted with an ImS microfocus
sealed-tube X-ray source, Apex II CCD detector, 4-circle Kappa goniometer and an
Oxford Cryostream 700 liquid nitrogen cooling system. The diffraction data sets
were indexed and scaled with the Bruker program SAINT (version v8.18c).
Molecular replacement solutions were obtained with the program Phenix26 using
PDB entry 4PKI (our crystal structure of the GS1-Tmod1ABS2:actin complex7).
Model building and reﬁnement were carried out with the programs Coot27 and
Phenix. Data collection and reﬁnement statistics are listed in Table 1.
Isolation of rat cardiomyocytes and cell transfection. Neonatal rat cardio-
myocytes were isolated and cultured as previously described28. Brieﬂy, neonatal rat
(Wistar Han) hearts were dissected and enzymatically digested with 0.5mgml 1
collagenase (Worthington Biochemical Corporation) and 0.6mgml 1 pancreatin
(Gibco). After plating in culture medium (DMEM supplemented with 4:1 Medium
199 (Life Technologies), 10% horse serum, 5% heat inactivated fetal bovine serum,
4mM glutamine and 1% penicillin–streptomycin) forB70min on uncoated plastic
to discard ﬁbroblasts, the cardiomyocytes were re-plated on collagen/ﬁbronectin-
coated plastic dishes (Nunc). The culture media was exchanged after 24 h for
maintenance media, consisting of 20% Medium 199, 4% horse serum, 4mM
glutamine, 1% penicillin–streptomycin, 0.1mM phenylephrine, 0.01mM cytosine
arabinoside and 75% DBSS-K (6.8 g l 1 NaCl, 0.14mM NaH2PO4, 0.2mM CaCl2,
0.2mM MgSO4, 1mM dextrose and 2.7mM NaHCO3). Cells were transiently
transfected with EGFP and mCherry constructs 24 h after isolation using Escort III
reagent (Sigma-Aldrich) according to the manufacturer’s speciﬁcations and
cultured in maintenance media until ﬁxation. For expression in mammalian cells,
Lmod and Tmod constructs, including Tmod1N (1–163), Tmod1ABS2 (164–351),
Lmod2N (1–179), Lmod2ABS2 (180–367), Lmod1N (1–298) and Lmod1ABS2
(299–486), were cloned between the XhoI and BamHI sites of vector pEGFP-N1
(Clontech) or NheI and KpnI sites of vector mCherry2-N1 (Addgene plasmid
# 54517).
Immunoﬂuorescence microscopy. Cells were ﬁxed 24 h post-transfection with
4% paraformaldehyde for 20min and permeabilized with 0.2% Triton X-100 in
PBS for 8min. Primary and secondary antibodies were diluted in PBS containing
0.2% BSA. Antibody dilutions were as follows: 1:200 monoclonal anti-a-actinin
(sarcomeric, clone EA-53 from Sigma-Aldrich) and 1:300 anti-myomesin (mMaC,
Developmental Studies Hybridoma Bank, University of Iowa). Speciﬁc secondary
antibodies conjugated to Alexa Fluor 647 (Life Technologies) were used at a
dilution of 1:250. After incubation with primary antibodies at room temperature
for 30min, dishes were washed at least three times for 10min each with PBS
containing 0.2% BSA, and then treated with ﬂuorescent secondary antibodies. After
an additional incubation for 30min at room temperature, the dishes were washed,
and square glass coverslips were mounted using Mowiol containing 10% DABCO
(1,4- diazabicyclo[2.2.2]octane). Plastic dish borders were cut away and the dishes
were mounted to slides. Images were acquired with an Orca-Flash4.0 V2 sCMOS
camera (Hamamatsu) on an upright Leica DM6000B ﬂuorescence wide-ﬁeld
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microscope equipped with a HCX PL APO  63/1.40-0.60 oil-immersion
objective. Image acquisition was carried out using the LAS X software (Leica).
Deconvolution of immunoﬂuorescence images was performed using
AutoQuant/AutoDeblur 2D non-blind Deconvolution (AutoQuant Imaging).
Fast Fourier transform analysis. Myoﬁbril line-scans were taken with the
program Fiji (ImageJ) for three different channels in cardiomyocytes co-expressing
full-length Tmod1, Lmod1 or Lmod2 along with their fragments, and co-stained
with anti-a-actinin antibodies. One-dimensional fast Fourier transform analysis
was performed on individual line-scans with the program Origin (version 7.0). The
resulting power spectra from 50 (Tmod1 and Lmod2) or 30 (Lmod1) line scans
were then averaged with the program Origin.
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